

1 High-resolution mapping and characterization of epitopes in 2 COVID-19 patients

3 Winston A. Haynes^{1,†}, Kathy Kamath^{1,†}, Joel Bozekowski^{1,†}, Elisabeth Baum-Jones¹, Melissa
4 Campbell², Arnau Casanovas-Massana³, Patrick S. Daugherty¹, Charles S. Dela Cruz⁴,
5 Abhilash Dhal¹, Shelli F. Farhadian⁵, Lynn Fitzgibbons⁶, John Fournier^{3,5}, Michael Jhatro¹,
6 Gregory Jordan¹, Debra Kessler⁷, Jon Klein⁸, Carolina Lucas⁸, Larry L. Luchsinger⁷, Brian
7 Martinez¹, Mary C. Muenker³, Lauren Pischel^{3,5}, Jack Reifert¹, Jaymie R. Sawyer¹, Rebecca
8 Waitz¹, Elsie A. Wunder Jr.³, Minlu Zhang¹, Yale IMPACT Team, Akiko Iwasaki^{8,9}, Albert I. Ko^{3,5},
9 John C. Shon^{1,*}

10

11 ¹ Serimmune, Inc., Goleta, CA, USA

12 ² Department of Pediatrics, Section of Pediatric Infectious Diseases, Yale School of Medicine,
13 New Haven, CT, USA

14 ³ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven,
15 CT, USA

16 ⁴ Department of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Yale School
17 of Medicine, New Haven, CT, USA

18 ⁵ Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven,
19 CT, USA

20 ⁶ Santa Barbara Cottage Hospital, Santa Barbara, CA, USA

21 ⁷ New York Blood Center, New York, NY, USA

22 ⁸ Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA

23 ⁹ Howard Hughes Medical Institute, Chevy Chase, MD, USA

24 [†] These authors contributed equally

25 ^{*} Correspondence to: john.shon@serimmune.com

26 Members of the Yale IMPACT Team:

27 Kelly Anastasio, Michael H. Askenase, Maria Batsu, Santos Bermejo, Kristina Brower, Molly L.

28 Bucklin, Staci Cahill, Yiyun Cao, Rupak Datta, Giuseppe Deluliis, Rebecca Earnest, Bertie

29 Geng, Ryan Handoko, William Khoury-Hanold, Lynda Knaggs, Maxine Kuang, Sarah Lapidus,

30 Anjelica Martin, Irene Matos, David McDonald, Maksym Minasyan, Adam J. Moore, Nida

31 Naushad, Allison Nelson, Jessica Nouws, Angela Nunez, Hong-Jai Park, Xiaohua Peng, Tyler

32 Rice, Kadi-Ann Rose, Wade Schulz, Lorenzo Sewanan, Lokesh Sharma, Denise Shepard,

33 Michael Simonov, Mikhail Smolgovsky, Nicole Sonnert, Ariktha Srivathsan, Yvette

34 Strong, Codruta Todeasa, Jordan Valdez, Sofia Velazquez, Pavithra Vijayakumar, Elizabeth B.

35 White

36

37 **Abstract**

38 Fine scale delineation of epitopes recognized by the antibody response to SARS-CoV-2

39 infection will be critical to understanding disease heterogeneity and informing development of

40 safe and effective vaccines and therapeutics. The Serum Epitope Repertoire Analysis (SERA)

41 platform leverages a high diversity random bacterial display library to identify epitope binding

42 specificities with single amino acid resolution. We applied SERA broadly, across human, viral

43 and viral strain proteomes in multiple cohorts with a wide range of outcomes from SARS-CoV-2

44 infection. We identify dominant epitope motifs and profiles which effectively classify COVID-19,

45 distinguish mild from severe disease, and relate to neutralization activity. We identify a

46 repertoire of epitopes shared by SARS-CoV-2 and endemic human coronaviruses and

47 determine that a region of amino acid sequence identity shared by the SARS-CoV-2 furin

48 cleavage site and the host protein ENaC-alpha is a potential cross-reactive epitope. Finally, we

49 observe decreased epitope signal for mutant strains which points to reduced antibody response

50 to mutant SARS-CoV-2. Together, these findings indicate that SERA enables high resolution of

51 antibody epitopes that can inform data-driven design and target selection for COVID-19
52 diagnostics, therapeutics and vaccines.

53

54 **Introduction**

55 The novel coronavirus SARS-CoV-2 global pandemic has affected millions of people
56 world-wide and led to a major healthcare crisis. Considerable research has gone into
57 understanding the myriad symptoms that are seen in patients as well as the stark contrast
58 between the large number of mild or asymptomatic cases and the staggering death toll around
59 the world¹⁻⁵. Determining the factors that contribute to different disease manifestations, severity
60 and immunity is critical to adequate therapeutic intervention, improved patient outcomes, and
61 vaccine design.

62 One avenue that is being extensively explored is the degree to which an immune
63 response to the virus protects, or harms, an individual. Although it is possible that a pre-existing
64 exposure to common coronaviruses may have a protective role during SARS-CoV-2 infection^{6,7},
65 it has also been proposed that antibodies to SARS-CoV-2 may sometimes be directly
66 pathogenic or lead to the generation of auto-reactive antibodies⁸⁻¹². With millions of cases
67 extant, and based on current trends, millions more in the coming months, it is critical that
68 patients be accurately assessed not just for infection but also for the potential of severe disease
69 progression, allowing timely application of treatments for best outcomes. Of considerable
70 concern as well is the specter of a combined SARS-CoV-2/influenza season with the need to
71 rapidly differentiate between multiple viral infections^{13,14}. In addition, a growing number of
72 COVID-19 patients who had expected to fully recover have not, with symptoms that linger far
73 past the expected recovery period and cause significant disruption to their lives as well as an
74 extended need for healthcare. The number of “long-haulers” is not currently clear but the need
75 to elucidate the role of a disrupted immune system in their illness is pressing¹⁵⁻¹⁷.

76 Of paramount urgency is the development of a vaccine against SAR-CoV-2. Along with
77 the initial step of defining an effective vaccine for the immediate crisis, factors such as viral
78 mutation rate and the uncertainty of long-term immunity could play a large role in ongoing
79 management. It is unclear if it will be possible to develop “sterilizing immunity” to the virus, thus
80 preventing infection completely^{18–20}. A yearly “flu-type” immunization would necessitate
81 continued surveillance of both viral evolution and patients’ yearly immune responses to keep
82 transmission and mortality to a minimum²¹.

83 Many different groups have examined antibody responses to SARS-CoV-2, exploring
84 correlation with disease severity, duration of humoral response, and the neutralizing capacity of
85 response^{3,22,23}. Most of these methods have been limited to quantitative assessment of humoral
86 response to whole proteins or large domains of spike and nucleoprotein. Peptide and phage
87 display libraries have also been used to capture higher resolution epitope patterns associated
88 with disease but are limited to characterization of linear epitope signal and in their ability to
89 make clinical seropositivity assessments^{4,24,25}. We present in this paper the application of Serum
90 Epitope Repertoire Analysis (SERA), a high throughput, random bacterial peptide display
91 technology that enables assessment of SARS-CoV-2 seropositivity and high-resolution mapping
92 of epitopes across any arbitrary proteome, including wild-type SARS-CoV-2, its mutant strains,
93 common coronaviruses, and the human proteome.

94 We have leveraged over 2,000 pre-pandemic immune repertoires and over 500 COVID-
95 19 cases to identify the antigens and epitopes that elicit a SARS-CoV-2 humoral response. We
96 show that while antibody profiles of individuals are heterogeneous, epitope-level resolution
97 enables a range of analyses and visualizations, from the earliest epitopes to elicit an antibody
98 response, to putative mapping of structural epitopes that may be important for neutralization or
99 immunity. Combining epitope motifs into a panel yields a diagnostic classifier that distinguished
100 NAT+ cases from controls with accuracy comparable to serological tests in current use.
101 Differences in the quantity and quality of epitopes in mild versus moderate and severe disease

102 can be seen at sites of biological and clinical interest. *In silico* analysis of epitope repertoires on
103 wild-type and mutant SARS-CoV-2 proteins suggests that some mutations may result in loss of
104 antibody reactivity to mutant SARS-CoV-2 infections while analysis against the human
105 proteome identified SARS-CoV-2 antibodies that may cross-react with human proteins and
106 contribute to disease pathogenesis. These capabilities are all possible through informatics
107 analysis of a single assay that requires a minimal amount of serum from each subject.

108

109 **Results**

110 *SERA screening of COVID-19 serum*

111 We applied SERA to discover and validate SARS-CoV-2 antigens and epitopes across
112 the complete viral proteome from 779 COVID-19 serum samples taken from multiple cohorts of
113 individuals with recent or past SARS-CoV-2 infection, which in total include 579 unique subjects
114 (Table 1). We additionally leverage a large database of 1997 pre-pandemic controls. The
115 majority of the subjects were confirmed SARS-CoV-2 positive by nucleic acid testing (NAT). For
116 Cohorts I, II, and III, extensive characterization was available for covariates that included
117 disease severity, date of symptom onset, and in many cases, serological testing (Supplemental
118 Table 1).

119 Patient samples were all screened using the previously published SERA assay, which
120 enables high throughput characterization of antibody epitopes (Figure 1)^{26,27}. In brief, serum or
121 plasma is incubated with the randomized bacterial display peptide library; antibodies bind to
122 peptides that mimic their natural epitopes and are then separated from unbound library
123 members using affinity-coupled magnetic beads. The resulting bacterial pools are grown
124 overnight, plasmids encoding the antibody-binding peptides are purified, and the peptide-
125 encoding regions are PCR amplified and barcoded with well-specific PCR indices. Ninety-four
126 samples are normalized, pooled together and sequenced via next-generation sequencing

127 (NGS). The output of SERA is a set of approximately 1 million peptide sequences for each
128 individual, representing their unique epitope repertoire. After SERA screening, we applied two
129 complementary discovery tools, IMUNE and PIWAS, to identify antigens and epitopes involved
130 in the SARS-CoV-2 immune response (Figure 1).

131

132 *Characterization of SARS-CoV-2 proteome antigens and epitopes*

133 To establish an understanding of relevant SARS-CoV-2 antigens and epitopes, we
134 analyzed the SARS-CoV-2 proteome with protein-based immunome wide association studies
135 (PIWAS). Briefly, PIWAS identifies epitope signal in the context of an arbitrary proteome by tiling
136 and smoothing kmer sequences across the entire proteome²⁸. PIWAS derives power at both the
137 cohort and single sample level through statistical comparisons to a large database of pre-
138 pandemic controls. Using the reference SARS-CoV-2 proteome from Uniprot, we performed
139 PIWAS of 579 COVID-19 samples compared to 497 pre-pandemic controls, with 1500 additional
140 pre-pandemic controls serving as a normalization cohort. In addition to the established antigens
141 spike and nucleocapsid, we observed highly significant signals for protein 3a, non-structural
142 protein 8 (NSP-8), membrane protein, and replicase polyprotein 1ab (Figure 2A). We further
143 examined epitope-level signal for the top IgG and IgM antigens identified by PIWAS (Figure 2B).
144 Within spike and nucleoprotein, we observed multiple epitopes that are conserved across a
145 large portion of the COVID-19 patient population. In contrast, epitope signals for protein 3a,
146 NSP-8, and membrane protein (IgM) are largely characterized by a single, dominant epitope.
147 While the receptor binding domain (RBD) of spike is highly important in host infection by the
148 virus, we observe no conserved epitope signal against this region of spike (amino acids 331-
149 524). Instead, we observe private spike epitopes in a subset of patients in our cohorts (Figure
150 2C, Figure S1). We highlight patients with epitopes observe in multiple longitudinal draws, to
151 decrease the likelihood of false positive signal.

152

153 *Unbiased, proteome-independent epitope analysis*

154 The IMUNE algorithm identified mapping and non-mapping epitope motifs that were
155 highly enriched in COVID-19 repertoires (Methods)²⁷. Linear epitopes identified by IMUNE
156 largely overlapped with those identified by PIWAS (Figure 2). The IgG linear motifs mapped to
157 epitopes on spike glycoprotein (n=10), nucleoprotein (n=8) and NSP8 (n=2). IgM linear motifs
158 mapped to a single epitope at the furin cleavage site on spike glycoprotein that was also a
159 target for IgG antibodies, as well as one epitope on the SARS-CoV-2 membrane protein. A
160 significant number of motifs identified by IMUNE did not directly map to linear regions of the
161 SARS-CoV-2 proteome. We have observed from studies with monoclonal antibodies that non-
162 mapping motifs tend to represent mimotopes of both linear and structural epitopes.

163 Motifs were selected for inclusion in the SARS-CoV-2 epitope map if they demonstrated
164 a specificity of at least 98% in 497 pre-pandemic controls (Methods). The resulting SARS-CoV-2
165 panel of 45 IgG and 14 IgM motifs was compiled into a semi-quantitative epitope map, enabling
166 visualization of motif enrichment for all evaluated COVID-19 and control samples (Figure 3A).
167 We observed that an unlabeled, hierarchical clustering of samples based on these motif
168 enrichments largely separates pre-pandemic control samples from COVID-19 patients.
169 Focusing on those motifs with linear hits to SARS-CoV-2, we further observed sub-clusters of
170 patients with reactivity to specific isotypes and antigens, from left-to-right: spike IgG+IgM, spike
171 and membrane IgM, spike IgM, nucleocapsid IgG, and broadly reactive.

172

173 *SARS-CoV-2 diagnostic panels can classify NAT+ samples with sensitivity comparable to*
174 *ELISA*

175 To develop a SARS-CoV-2 diagnostic panel, we selected a subset of peptide motifs that,
176 in the training cohort, either exhibited high sensitivity and specificity or improved the breadth of
177 coverage (Supplemental Table 2). We normalized and summed motif enrichments to generate
178 a composite score and compared sub-panels to identify the panel with the maximal diagnostic

179 performance on the training cohort (Methods). A composite score of ≥ 25 was set as a cutoff for
180 both IgG and IgM panels to obtain a specificity of $\geq 99\%$ on the pre-pandemic training controls
181 (Table 1). The panel performance was evaluated on a test cohort of 427 COVID-19 samples
182 that were confirmed positive by NAT testing (Table 1, testing cohorts I-III). The classifier with the
183 best overall performance is shown in Figure 3B. The sensitivity varied between 54% and 82%
184 across the NAT+ cases from different cohorts, primarily based on the timing of blood collection
185 relative to symptom onset for each cohort. A specificity of 99.3% for IgG and 99.1% for IgM was
186 achieved on a test set of 1500 pre-pandemic repertoires that were tested for acute illness.
187 Combining the IgG and IgM panels into a single test resulted in a panel specificity of 98.7%.
188 Notably, no pre-pandemic samples were co-positive for IgG and M, thus the specificity for
189 subjects that were positive for both IgG and IgM was 100% in the test control set. Forty-two
190 percent of all tested COVID-19 samples met these criteria.

191 We plotted the SERA scores for samples from cohorts I and II, where timing of the blood
192 draw relative to date of symptom onset was provided (Figure 3B). The panel exhibited a
193 sensitivity of 47% at 0-5 days after symptom onset, 64% at 5-10 days and $\geq 90\%$ at >10 days
194 post symptom onset. Where predicate SARS-CoV-2 ELISA results were available, we
195 compared performance relative to SERA in SARS-CoV-2 NAT+ samples. Overall, SERA IgG
196 and IgM panels together demonstrated similar sensitivity to three different ELISAs in current use
197 (95% CI, Wilson score) (Table 2).

198

199 *Structural epitope mapping*

200 To further interrogate functional relevance of the identified motifs, we mapped motifs to
201 the surface of published SARS-CoV-2 spike glycoprotein crystal structures. We observed that
202 the linear motif LPFQQ, which has been previously implicated as a neutralizing epitope²⁵,
203 mapped to a single location on the surface of spike glycoprotein (Figure 3C). Using these same
204 methods, we examined possible structural maps of motifs without linear maps to SARS-CoV-2.

205 We highlight one exemplary motif, YWXYFXK which was found to map to the RBD of spike
206 glycoprotein (Figure S2). Based on our previous observations that tryptophan tends to confer
207 structural characteristics on our peptide epitopes, we additionally examined the mapping of the
208 slightly modified motif YXXYFXK which we found also maps strongly to spike (Figure 3C). In
209 addition to the highlighted match to spike, YXXYFXK had two less feasible maps to spike
210 glycoprotein (Figure S2).

211 We also investigated the potential neutralization capacity of these motifs. We plotted the
212 neutralization titer of each sample against the enrichment of the motif in those samples (Figure
213 3D). For both motifs, we observed that higher enrichment values tended to be present in
214 patients with higher titer neutralization activity.

215

216 *Motifs and epitopes associated with disease severity*

217 Based on prior studies that described subjects with severe disease possessing a
218 stronger and, perhaps, earlier humoral IgG response in both spike and nucleoprotein relative to
219 subjects with mild disease^{29,30}, we examined differences in epitope severity detected by SERA.
220 We compared the SERA IgG panel score (developed to distinguish COVID-19 patients from
221 pre-pandemic controls) across the spectrum of severities present in our population (Figure 4A).
222 We observed a significant elevation of the panel score in patients with severe or moderate
223 disease compared to their mild disease counterparts. To understand the specific epitopes
224 driving the severity delineation, we identified the 10 motifs with the most significant t-test p-value
225 when comparing severe and mild disease (Figure 4B). We observe a potential confounding of
226 days since onset of symptoms with the SERA IgG score (Figure S3). All 10 motifs were
227 identified in the IgG screen and 9 out of 10 motifs did not possess a linear map to SARS-CoV-2.
228 In the hierarchical clustering of samples, we observe subsets of severe patients with preferential
229 enrichment for differing motifs. After splitting our data into 2/3 training and 1/3 testing cohorts,

230 we built a simple LASSO model to classify moderate/severe from mild disease, and observed
231 encouraging performance (training AUC 0.92, testing AUC 0.9, Figure S3).

232 One of the distinguishing features of the SARS-CoV-2 coronavirus is the acquisition of
233 polybasic residues (RRAR) at the cleavage site of the S1/S2 boundary. Cleavage of spike
234 protein at this site is required to enable viral membrane fusion^{31,32}. It has been proposed that
235 this novel sequence enables the virus to take advantage of host proteases, such as furin, that
236 cleave proteins with this recognition sequence, thereby increasing the potential tropism of the
237 virus relative to other coronaviruses^{31,33}. We asked if this site elicited an immune response, and
238 if so, was it seen differentially in subjects with different disease severity. In the spike epitope
239 map, signal at this sequence location is both prominent and prevalent in the cohorts — 120 out
240 of 385, or 31% of subjects, had epitope signals >99% of that seen in controls. We also
241 determined that the site elicited a statistically significantly stronger immune response in subjects
242 with severe disease relative to subjects with mild or moderate disease (Figure 4C). Specifically,
243 39%, 23%, and 20% of severe, moderate, and mild cases, respectively, had strong epitope
244 signals greater than 99% of that in the controls.

245 The novel eight amino acid furin cleavage site (RRAR|SVAS) in spike maps identically to
246 a peptide sequence in one protein in the human proteome, the amiloride sensitive sodium
247 channel ENaC- α protein³³. This protein is expressed on the surface of multiple tissues
248 implicated in COVID-19 pathology, and similar to spike, requires cleavage for activation. As the
249 sites share the eight amino acid furin cleavage sequence, not surprisingly, we see a highly
250 correlated PIWAS immune signal in both proteins (Figure S3) that is also statistically stronger in
251 severe disease relative to mild or moderate disease (Figure 4D). We also note that in severe
252 cases, a number of very strong epitopes in ENaC- α outside of the cleavage site are seen
253 relative to mild cases. The signal at both sites was also seen to increase over time, particularly
254 between 2 and 4 weeks, indicating a likely adaptive immune response to this site (Figure S3).

255 In addition to spike and nucleoprotein, a robust immune response has been described
256 against the ORF8 protein³⁴. Several reports have described a variant of SARS-CoV-2 with a
257 382-nucleotide deletion in ORF7b and ORF8 as well as an association of the deletion with a
258 milder disease course³⁵. While we do not have genotype information for all strains, based on the
259 GISAID database we assume that most of the samples in our cohorts do not have this deletion.
260 To explore the possible association of immune response with disease severity, we analyzed the
261 PIWAS signal against ORF8, which encompasses most of the 382-nucleotide deletion. While
262 there appear to be more extremely high signals in severe cases, using an outlier sum statistic,
263 the PIWAS signal in ORF8 does not reach statistical significance in severe cases relative to mild
264 and moderate cases (Figure 4E, F).

265

266 *PIWAS prediction of antibody cross-reactivity to other coronaviruses*

267 We next investigated SARS-CoV-2 epitopes that may cross-react with other
268 coronaviruses as previous exposure to coronaviruses could have protective or even deleterious
269 effects on symptoms^{6,7}. To identify potential cross-reactive epitopes, we performed PIWAS
270 using the epitope repertoires from COVID-19 samples against various coronavirus proteomes,
271 including SARS-CoV-2, SARS-CoV (SARS), MERS, and the four common human
272 coronaviruses (hCoVs) HKU1, OC43, 229E, and NL63. Analysis of average PIWAS values for
273 spike glycoprotein across coronaviruses revealed epitopes that were conserved in many
274 coronaviruses as well as epitopes that were specific to SARS-CoV-2 (Figure 5A). We identified
275 10 epitopes enriched against the SARS-CoV-2 proteome (average PIWAS >0.5), two and one
276 of which overlapped with OC43 and NL63 epitopes, respectively. For example, the region
277 corresponding to spike 809-834 in SARS-CoV-2 (alignment indices 1140-1170) contained an
278 epitope that was observed against all coronaviruses analyzed (Figure 5B). However, at spike
279 1141-1162 in SARS-CoV-2 (alignment indices 1500-1525) an epitope was observed only
280 against SARS-CoV-2, SARS, MERS, and OC43 proteomes, with OC43 exhibiting the highest

281 average PIWAS value. After evaluating enrichment for these cross-reactive spike epitopes in
282 COVID-19 cases with different disease severity, we found there was no statistical difference
283 between severe, moderate, and mild cases (Figure 5C).

284 In contrast to spike, nucleoprotein exclusively contained epitopes specific to SARS-CoV-
285 2 and SARS, with 4 epitopes against the SARS-CoV-2 proteome (Figure 5D). Strong epitopes
286 were observed against SARS-CoV-2 at regions 150-178 (alignment indices 165-195) and 392-
287 419 (alignment indices 480-510) with no signal observed against hCoVs (Figure 5E). We
288 determined that these nucleoprotein epitopes were significantly enriched in severe and/or
289 moderate cases compared to mild cases (Figure 5F).

290

291 *Epitope signal in mutated SARS-CoV-2 strains*

292 To study the possible effects of known mutations to the SARS-CoV-2 virus on antibody
293 response, we leveraged the ability of PIWAS to interrogate the SERA database with any
294 sequence of interest. In the 96,437 sequenced strains from GISAID, we enumerated 21,127
295 distinct amino acid mutations to spike glycoprotein, nucleoprotein, envelope protein, and
296 membrane protein^{36,37}. For each mutation, we compared epitope signal against the wild-type
297 (WT) and mutant position in every COVID-19 specimen. We observed a bias towards mutations
298 yielding a decreased PIWAS signal relative to WT (Figure 6A). A subset of these mutations
299 yielded decreased signal across a large number of COVID-19 patients (Figure 6B). To assess
300 the significance of this decreased epitope signal, we *in silico* randomly mutated amino acids
301 throughout the same protein sequences as a null distribution. The Kolmogorov-Smirnov test
302 comparing the observed and null distributions was highly significant ($p=3e-11$), indicating that
303 the bias towards mutants that generate a decreased epitope signal exceeds that which would
304 be explained purely due to chance (Figure S4). For membrane protein, nucleoprotein, and spike
305 glycoprotein, we highlight exemplar mutations which resulted in decreased epitope signal
306 across a large number of patients (Figure 6C) and, in the case of spike glycoprotein, are on the

307 surface of the protein according to the crystal structures considered in this paper^{31,32}. In
308 contrast, the dominant spike glycoprotein D614G exhibits no epitope signal for either the wild-
309 type or mutant strains (Figure 6D).

310

311 **Discussion**

312 While conventional serology is a cornerstone of infectious disease diagnosis, the
313 COVID-19 pandemic has raised many questions not answered by these testing modalities
314 alone. Here we have shown that high-content random bacterial peptide display library screening
315 using SERA provides a tool to broadly and deeply probe individual antibody repertoires. These
316 profiles, both individually and in the aggregate, can yield insights into disease severity,
317 immunity, cross-reactivity to other coronaviruses (including SARS-CoV-2 mutant strains), and
318 autoimmune sequelae.

319 By taking a focused, proteome-constrained approach to identifying signal against the
320 SARS-CoV-2 proteome, we both reiterate the established immunological relevance of spike and
321 nucleoprotein as well as identify less described signals against protein 3a and NSP-8. Epitope-
322 level characterization of these antigens highlights particularly immunogenic epitopes within each
323 protein, which might serve as targets in the development of vaccines and therapeutics. In
324 particular, we identified strong epitopes in nucleoprotein including at amino acids 158-172 and
325 the C-terminal domain 380-419, as well as epitopes in spike glycoprotein including at amino
326 acids 555-572, 810-828, and 1145-1159, consistent with previous studies^{4,24,38}. Additionally, we
327 highlight novel and less-studied epitopes, including a dominant IgM epitope from membrane
328 protein (amino acids 1-12) which could provide utility in early diagnostics. While we did not
329 observe spike RBD epitopes that were conserved across the patient cohort, we found
330 compelling examples of private RBD epitopes. The lack of linear epitopes towards spike RBD is
331 unsurprising given the complex structural nature of spike, with many strands running in parallel

332 likely yielding an abundance of structural mimotopes (also reflected in the quantity of non-
333 mapping motifs in our diagnostic panel).

334 Leveraging our database of thousands of pre-pandemic repertoires collected from
335 healthy individuals as well as people with infections, autoimmune diseases, and cancer across
336 all age groups and geographies, we were able to assess the specificity of the SARS-CoV-2
337 antibody response and identify a panel of epitopes that could distinguish COVID-19 cases from
338 controls with accuracy similar to conventional serological testing.

339 We further investigated the possible origins of the non-mapping motifs by attempting to
340 map them structurally to spike glycoprotein. We validated the mapping by showing that it
341 accurately identifies the linear motif LPFQQ, and then applied the method to non-mapping
342 motifs. We find that the motif YWXYFXK exclusively maps to the RBD. However, previous
343 observations have suggested that tryptophan (W) may be more important for conferring
344 structure to the mimotope than for identity mapping, yet still the more general motif YXXYFXK
345 maps to RBD as well. When combined with the neutralization titers of samples in which this
346 motif is enriched, it is possible to speculate about the mechanism of neutralization. If the
347 antibodies that recognize this motif bind to the RBD of spike glycoprotein, they may block the
348 ability of SARS-CoV-2 to bind to ACE2 and inhibit viral entry and infection.

349 One of the ongoing areas of development in this approach is that while we have
350 assumed that the identity of the residues remains constant between motif and the epitope, it is
351 possible that amino acid substitutions could be allowed. We have attempted a first pass to
352 mitigate this by allowing for a more general mapping with the modification of the W to an X, but
353 we continue to iterate on this model to more accurately account for residue mismatches in
354 mapping motifs to the structure. While these methods are still under development, the results
355 here demonstrate the applications of such a method.

356 Consistent with previous studies, we find that the humoral immune response against
357 SARS-CoV-2 is stronger in severe and moderate disease relative to mild disease^{4,39,40}. This

358 finding is consistent with a general pattern of disease associated with immunopathology in
359 COVID-19. We also identified specific epitope profiles that correlate with disease severity and
360 combined these epitopes into a preliminary disease severity classification model. To further
361 validate these findings we would require a separate, validation cohort of patients which span
362 mild and severe disease states. Importantly, many of our disease severity analyses are
363 potentially confounded by the number of days since onset of symptoms in the COVID-19
364 subpopulations, partially due to the challenge of both identifying disease onset in mild patients
365 and collecting samples from non-hospitalized patients.

366 Using *in silico* analysis of repertoires on the human proteome, we are also able to
367 identify candidate cross-reactive or novel autoantigen epitopes that may be important in disease
368 pathogenesis. The polybasic cleavage site seen in SARS-CoV-2 is unique among
369 coronaviruses and potentially enables it to increase its tissue tropism³³. We demonstrate that
370 the immune response at this site is predicted to be both significantly prominent and prevalent
371 relative to a pre-pandemic cohort, as well as significantly stronger in severe and moderate
372 versus mild disease. The sequence is shared with the amiloride sensitive sodium channel
373 ENaC- α , which is responsible for sodium influx into tissue⁴¹. Disruption of this channel in
374 individuals with variants has been associated with pulmonary edema and alveolar fluid
375 overload^{40,42}. Thus, this channel has been investigated in SARS-CoV-2 and other respiratory
376 illnesses for possible pathogenic implication in disease and as a target for therapy⁴³.

377 Our finding that immune signal at this site is significantly elevated suggests the
378 possibility of molecular mimicry with potential pathogenic consequences. While we do not have
379 direct evidence of binding of antibody to ENaC- α at this site, functional blockage of the site
380 could be postulated to prevent the cleavage of the ENaC- α channel, which is necessary for
381 channel activation⁴³. The signal against this site increases over time in the majority of cases
382 indicating an adaptive immune response, but the effect of this response on pathogenicity is
383 unclear as binding at the spike site could in fact reduce infectivity of the virus. A recent study

384 has also noted that binding at this site reduces the RBD-ACE2 binding energy, and therefore
385 could be a potential site for neutralizing antibodies⁴⁴. Functional analyses and experiments are
386 thus required to investigate whether cross-reactivity occurs and to distinguish the effect of
387 antibodies binding to either the viral or host antigens at this site. The ability to query potential
388 autoantigen signal using SERA in the context of SARS-CoV-2 infection and epitopes is an area
389 for continued inquiry given the mounting data supporting the significance of autoantigens in the
390 immunopathology of COVID-19^{10,45}.

391 Milder disease has been described in subjects with the 382-ORF8 deletion variant, and
392 the ORF8 protein has been noted to be associated with strong humoral response^{35,46}. In our
393 study, we also see significant response relative to a pre-pandemic cohort in ORF8. While a few
394 epitopes appear quite strong in some individuals in ORF8 with severe disease, the overall signal
395 across the antigen was not seen to be statistically significant in mild versus severe disease.
396 Specific, strong epitope signals in ORF8 could be postulated to contribute to severe disease
397 through a variety of mechanisms, but this would also need to be explored through further
398 epidemiological and experimental analysis.

399 By evaluating epitope signal in COVID-19 cases against common human coronavirus
400 (hCoV) proteomes, we predicted prevalent cross-reactive epitopes particularly in the S2 domain
401 of spike. Given the strength and prevalence of these cross-reactive epitopes, it is plausible that
402 previous exposure to hCoVs contributed to these antibody responses, a boosting phenomenon
403 recently described in COVID-19 cases⁴⁷. In particular, the cross-reactive epitope at spike amino
404 acids 809-834 near the fusion domain has been shown to elicit an antibody response in SARS-
405 CoV-2 uninfected adolescents and adults⁴⁸. Interestingly, antibodies targeting this epitope
406 demonstrated neutralizing capacity using antibody depletion assays³⁸. More broadly, the
407 presence of spike-reactive T cells in healthy donors has been observed against SARS-CoV-2 as
408 well as hCoVs 229E and OC43, primarily reactive towards the spike S2 domain⁶. While these
409 findings suggest a role for cross-reactive epitopes in the response to SARS-CoV-2 infection, it is

410 uncertain what impact pre-existing antibodies have towards protection, immunity, and disease
411 progression. Recent studies suggest that pre-existing antibodies from hCoVs exist but are not
412 associated with protection^{47,49}. We observed that prevalent cross-reactive epitopes in spike
413 were not associated with COVID-19 severity while multiple nucleoprotein epitopes specific to
414 SARS-CoV-2 and SARS were significantly enriched in severe cases compared to mild. Notably,
415 it has been shown that convalescent COVID-19 patients exhibited a shift in antibody response
416 towards spike compared to a nucleoprotein-directed antibody response in deceased patients³.
417 Given that cross-reactive epitopes were observed in spike, additional investigation will be critical
418 towards understanding pre-existing antibody responses that may impact SARS-CoV-2 infection
419 and COVID-19 progression.

420 The decreased epitope signal in COVID-19 patients against mutant strains of SARS-
421 CoV-2 compared to WT is suggestive of evolutionary evasion of the antibody response⁵⁰⁻⁵².
422 Under this hypothesis, SARS-CoV-2 strains are undergoing selective pressure to evade
423 antibody response, resulting in strains that may be less susceptible to clearance by those
424 previously infected with wild-type SARS-CoV-2^{53,54}. While these observations do not inherently
425 indicate greater infectivity, the public health consequences of epitope mutation are concerning
426 and further suggestive of the potential for the SARS-CoV-2 virus to periodically re-emerge and
427 reinfect individuals with prior exposure. While not conclusive, these observations reveal the
428 importance of monitoring epitope mutations and could be used to guide therapeutic and vaccine
429 development efforts to focus on epitopes that are less susceptible to evasion, which would be
430 more broadly cross-reactive and robust to evolutionary changes.

431 The dominant strain of SARS-CoV-2 which is now in circulation possesses the D614G
432 mutation. Based on our data, neither the wild-type nor the mutant confer a significant linear
433 epitope, consistent with observations that the mutation is most notable for its effect on the
434 structure of spike⁵⁵.

435 We acknowledge various limitations with the SERA platform that impact this study. Much
436 of this study has focused on dominant epitopes prevalent in COVID-19 cases, but many of the
437 private epitopes not explicitly discussed here, particularly in spike RBD, are critical to fully
438 understanding the protective antibody response and clinical outcomes. Moreover, there are
439 clear limitations for probing the epitope repertoire with linear peptides, chiefly the challenges of
440 identifying structural epitopes and the role of post-translational modifications such as glycans⁵⁶.
441 While a random peptide library enables unique opportunities to identify structural mimics, much
442 work remains in cataloguing and mapping these mimics to their cognate antigens.

443 In summary, we present the application of SERA to assess SARS-CoV-2 seropositivity
444 and to characterize a high-resolution map of motifs and epitopes in individuals and populations.
445 We demonstrate the ability of the platform to assess disease severity, to identify structural
446 motifs associated with neutralization, to compare *in silico* epitope response to multiple
447 coronavirus strains, to assess potential immune escape at sites of variation, to evaluate
448 longitudinal changes in signal, and to reveal potential autoantigen response, all with one assay.
449 The random nature of the libraries, the ability to identify linear mimics of structural epitopes, and
450 the ability to leverage quality-controlled reference data from a large pre-pandemic cohort all
451 contribute to SERA's ability to elucidate the humoral immune response in SARS-CoV-2
452 infection.

453 Our findings support those of other studies that find clear differences in the humoral
454 response of individuals with different clinical severity and trajectories. While we may identify
455 associations between high resolution epitope and motif signals and disease severity, much work
456 is required to establish functional or causal relationships. Examining and correlating epitopes to
457 clinical efficacy in the context of vaccines and therapeutic antibodies will help to elucidate the
458 connection between measured immune response and patient outcome.

459 Yet the epitope landscape can change, as it is already clear that coronaviruses mutate
460 and SARS-CoV-2 is no exception. Potential changes in the infectivity of the virus in just this first

461 year of the current health crisis underscore the need to track evolving immune responses and
462 clinical features in populations world-wide^{55,57-60}. We have demonstrated the ability to capture
463 and query both past and present repertoires through analysis of both pre-pandemic and current
464 pandemic samples. Using SERA to observe longitudinal immune responses against the human
465 proteome and coronavirus in the context of persistent symptoms or reinfection enables
466 construction of a detailed picture of infection, immunity and disease in COVID-19. SERA's ability
467 to query against any variant or future emerging genomes can be used to support ongoing
468 management of the current health crisis and future novel outbreaks.

469

470 **Materials and Methods**

471 *Biospecimens and Cohorts*

472 Sera or plasma from confirmed or suspected COVID-19 cases were acquired from Yale,
473 Santa Barbara Cottage Hospital (SBCH), LabCorp, BioIVT and Blood Centers of America
474 (BCA). Samples were de-identified prior to receipt at Serimmune. All samples and associated
475 metadata are shown in Supplemental Table 1.

476

477 *Yale cohort*

478 Samples were acquired as part of the Yale IMPACT biorepository study. The cohort
479 included inpatients that tested positive by PCR for SARS-CoV-2, outpatients with suspected
480 disease based on symptoms and Health Care Workers (HCW) that became positive by serial
481 PCR or serology testing every 2 weeks. COVID-19 cases were classified as mild if patients
482 were not hospitalized, moderate if hospitalized, and severe if on high-flow nasal canula, BiPAP
483 or other non-invasive ventilation, intubated or died from COVID-19. Participation in the study
484 was voluntary and the study protocol was approved by the Yale Institutional Review Board.

485

486 *SBCH cohort*

487 Biobanked sera or plasma from individuals that previously tested positive for COVID-19
488 were provided by the SBCH Biobank. Clinical data, including age, sex, and disease severity
489 were obtained by SBCH staff for inclusion in the biobank. Specimens were collected from both
490 inpatient and ambulatory settings and were coded as asymptomatic, mild/moderate if the
491 subject had symptoms consistent with COVID-19, or severe if the individual required admission
492 to the ICU for symptoms. Participation in these studies was voluntary and the study protocol
493 was approved by the SBCH Institutional Review Board.

494

495 *LabCorp cohort*

496 The majority of samples were remnant sera from acutely ill, ICU hospitalized, PCR
497 confirmed COVID-19 cases with high IL-6 test results (n=235). These cases were classified as
498 severe disease. An additional ten suspected COVID-19 cases were from individuals with mild
499 symptoms. A subset of these had serological evidence of infection by anti-RBD ELISA and/or
500 neutralization assay data.

501

502 *BioIVT cohort*

503 Remnant serum samples with serological evidence of infection by a positive Epitope EDI
504 IgG test (n=20) or a positive NAT test (n=1) were purchased from BioIVT. A subset had disease
505 severity characterization provided by the vendor.

506

507 *BCA cohort*

508 Plasma samples were collected from healthy blood donors in New York during the
509 period of March–July of 2020 as part of a collaboration with The Blood Centers of America. Two
510 samples included in the study were collected from COVID-19 plasma donors with confirmed
511 disease. Suspected COVID-19 cases included in the study had serological evidence of infection

512 based on a positive SERA IgG or IgM result that was subsequently confirmed by S1 spike and
513 nucleocapsid ELISA IgG in the majority of cases. Cases from healthy donors were classified as
514 mild disease.

515

516 *SERA serum screening*

517 A detailed description of the SERA assay has been published²⁶. For this study, serum or
518 plasma was incubated with a fully random 12-mer bacterial display peptide library (1×10^{10}
519 diversity, 10-fold oversampled) at a 1:25 dilution in a 96-well, deep well plate format. Antibody-
520 bound bacterial clones were selected with 50 μ L Protein A/G Sera-Mag SpeedBeads (GE Life
521 Sciences, cat#17152104010350) (IgG) or by incubation with a biotinylated anti-human IgM
522 antibody (Jackson ImmunoResearch, cat# 709-066-073) final assay dilution 1:100, followed by
523 a second incubation with 50 μ L Dynabead MyOne Streptavidin T1 conjugated magnetic beads
524 (IgM) (Thermo-Fisher 65602). The selected bacterial pools were resuspended in growth media
525 and incubated at 37°C shaking overnight at 300 RPM to propagate the bacteria. Plasmid
526 purification, PCR amplification of peptide encoding DNA, barcoding with well-specific indices
527 was performed as described²⁶. Samples were normalized to a final concentration of 4nM for
528 each pool and run on the Illumina NextSeq500.

529

530 *Spike S1 and nucleoprotein ELISA*

531 The SARS-CoV-2 Spike S1 and N antigen ELISA data were provided by Yale and
532 LabCorp. Spike S1 and nucleoprotein ELISAs on the SBCH COVID-19 samples were performed
533 in house using recombinant proteins (ACRO Biosystems, S1N-C52H3 and NUN-C5227,
534 respectively). A cut-off value for positivity was established using 3 times the standard deviation
535 of 502 pre-pandemic controls for the IgG and 82 pre-pandemic controls for IgM assays. Briefly,
536 plates (Nunc MaxiSorp) were coated with recombinant proteins, 0.5 μ g/ml for IgG and 1 μ g/ml
537 for IgM at 4°C overnight. After washing, plates were blocked with PBS containing 5% non-fat

538 milk for 2 hours at room temperature. Plates were then incubated with serum diluted 1/250 in
539 blocking buffer for 1 hour at room temperature. Plates were washed, then incubated with HRP-
540 goat anti-human IgG or HRP-donkey anti-human IgM (Jackson ImmunoResearch) secondary
541 antibody diluted 1/10,000 in blocking buffer for 1 hour at room temperature. After washing, the
542 reaction was developed with 3,3',5,5'-teramethylbenzidine substrate solution (ThermoFisher) for
543 15 minutes and stopped with 1M HCL. The absorbance was measured on a Tecan Spectrafluor
544 plus plate reader at 450 nm.

545

546 *Cell lines and virus*

547 VeroE6 kidney epithelial cells) were cultured in Dulbecco's Modified Eagle Medium
548 (DMEM) supplemented with 1% sodium pyruvate (NEAA) and 5% fetal bovine serum (FBS) at
549 37°C and 5% CO₂. The cell line was obtained from the ATCC and has been tested negative for
550 contamination with mycoplasma. SARS-CoV-2, strain USA-WA1/2020, was obtained from BEI
551 Resources (#NR-52281) and was amplified in VeroE6 cells. Cells were infected at a MOI 0.01
552 for four three days to generate a working stock and after incubation the supernatant was
553 clarified by centrifugation (450g × 5min) and filtered through a 0.45-micron filter. The pelleted
554 virus was then resuspended in PBS then aliquoted for storage at – 80°C. Viral titers were
555 measured by standard plaque assay using Vero E6 cells. Briefly, 300ul of serial fold virus
556 dilutions were used to infect Vero E6 cells in MEM supplemented NaHCO₃, 4% FBS 0.6%
557 Avicel RC-581. Plaques were resolved at 48hrs post infection by fixing in 10% formaldehyde for
558 1 hour followed by with 0.5% crystal violet in 20% ethanol staining. Plates were rinsed in water
559 to plaques enumeration. All experiments were performed in a biosafety level 3 with the Yale
560 Environmental Health and Safety office approval.

561

562 *Neutralization assay*

563 Patient and healthy donor sera were isolated as before and then heat treated for 30m
564 at 56 °C. Sixfold serially diluted plasma, from 1:3 to 1:2430 were incubated with SARS-CoV-2
565 for 1 h at 37 °C. The mixture was subsequently incubated with VeroE6 cells in a 6-well plate for
566 1hour, for adsorption. Then, cells were overlaid with MEM supplemented NaHCO₃, 4% FBS
567 0.6% Avicel mixture. Plaques were resolved at 40hrs post infection by fixing in 10%
568 formaldehyde for 1 hour followed by staining in 0.5% crystal violet. All experiments were
569 performed in parallel with negative controls sera, at an established viral concentration to
570 generate 60-120 plaques/well.

571

572 *PIWAS analysis*

573 We applied the previously published PIWAS method²⁸ to identify antigen and epitope
574 signals against the Uniprot reference SARS-CoV-2 proteome (UP000464024)⁶¹. The PIWAS
575 analysis was run on the IgG SERA data with a single sample per COVID-19 patient (for a total
576 of 579 patients) versus 497 discovery pre-pandemic controls, and the 1500 validation controls
577 used as the normalization cohort. Additional parameters include: a smoothing window size of 5
578 5mers and 5 6mers; z-score normalization of kmer enrichments; maximum peak value; and
579 generation of epitope level tiling data. Antigens were ranked using the Mann-Whitney U false
580 discovery rate, following the hypotheses of conserved epitopes in the context of infectious
581 disease. For top antigens, tiling data was generated for every case and control sample. 95th
582 quantile bands were calculated based on each population separately. The most significant RBD
583 epitopes were identified in COVID-19 patients with draws from at least 2 timepoints and a
584 PIWAS value of at least 6 occurring between the 319th and 541st amino acids.

585

586 *IMUNE-based motif discovery*

587 Peptide motifs representing epitopes or mimotopes of SARS CoV-2 specific antibodies
588 were discovered using the IMUNE algorithm²⁷. A total of 164 antibody repertoires from 98

589 hospitalized subjects from the Yale IMPACT study were used for motif discovery. The majority
590 of subjects were confirmed SARS CoV-2 positive by nucleic acid testing (NAT). IMUNE
591 compared ~30 disease repertoires with ~30 pre-pandemic controls and identified peptide
592 patterns that were statistically enriched (p value ≤ 0.01) in $\geq 25\%$ of disease and absent from
593 100% of controls. Multiple assessments were run with different subsets of cases and controls
594 both for IgG and IgM. Peptide patterns identified by IMUNE were clustered using a PAM30
595 matrix and combined into motifs. The output of IMUNE included hundreds of candidate IgG and
596 IgM motifs. A motif was classified as positive in a given sample if the enrichment was ≥ 4 times
597 the standard deviation above the mean of the training control set. The candidate motifs were
598 further refined based on at least 98% specificity. The final set of motifs was validated for
599 sensitivity and specificity on an additional 1500 pre-pandemic controls and 406 unique
600 confirmed COVID-19 cases from four separate cohorts (test cohorts I-IV, Table 1).

601

602 *Development of a diagnostic classifier for COVID-19*

603 To generate a diagnostic score that classified subjects as serologically positive for
604 antibodies to COVID-19, motif enrichment values were normalized using the mean and standard
605 deviation of enrichments within the training set of pre-pandemic control repertoires. Individual
606 SARS-CoV-2 motif normalized “z-scores” were then summed to obtain a composite score for
607 each sample. A composite score of 25 was established as a cutoff for positivity for each panel to
608 obtain a specificity of $>99\%$ on the pre-pandemic training controls.

609

610 *Structural motif mapping*

611 Structural motif mapping was carried out by identifying a network of neighboring
612 residues on the surface of a protein structure and looking in that network for matches to the
613 motif of interest. Neighboring residues were residues which had α -carbons within 8 Å. The
614 surface of the protein structure was calculated using the MSMS program⁶² with a probe radius

615 of 2.5 Å. These values are line with other algorithms for mapping mimotopes to structures^{63,64}
616 and were further optimized using our in-house dataset of monoclonal antibodies (data not
617 shown).

618 Once each match to a motif was found in the surface network of neighbors, each residue
619 is scored by the number of ways it was found to match to a motif. For example, the motif SE[RI]
620 might map to SER on the surface, and additionally to SEI on the surface, where the same S and
621 E are used. In this case, S would have a value of 2, E would have a value of 2, while R would
622 get a value of 1, and I would get a value of 1. Each residue was then colored according to these
623 values to produce the heat maps shown in the figures.

624 Structures used were downloaded from rcsb.org^{65,66}. Due to the recent focus on SARS-
625 CoV-2 there are many structures for spike glycoprotein in PDB. The following structures were
626 chosen due to their high sequence coverage, and in order to represent a variety of
627 conformations and binding states to ACE2: 6ZGG,6ZGI,7A93,7A95,7A97^{31,32}. PDB structures
628 were processed with Biopython^{67,68} and visualized with PyMol⁶⁹.

629

630 *Mild versus severe disease analysis*

631 For samples where clinical severity was known, we compared SERA IgG panel scores
632 using the outlier sum statistic^{28,70}. Using a t-test, we compared enrichments for all IgG and IgM
633 motifs between the severe/moderate and mild populations. The 10 most significant motifs were
634 highlighted and hierarchically clustered (Euclidean distance, Ward clustering⁷¹). Severity based
635 on PIWAS signal against the furin cleavage and ORF8 regions was similarly compared using
636 the outlier sum statistic. To identify potential auto-antigenic signal against ENAC- α , a PIWAS
637 analysis was performed (using the same parameters as above) using the Uniprot⁶¹ reference
638 human proteome (UP000005640).

639

640 *Common coronavirus analysis*

641 We identified Uniprot reference proteomes for the four common human coronaviruses
642 [OC43 (UP00007552), HKU1 (UP000122230), 229E (UP0006716), and NL63 (UP000145724)]
643 and more severe strains [SARS (UP000000354) and MERS(UP000171868)]⁶¹. For each
644 proteome, we ran a PIWAS with the same parameters as the SARS-CoV-2 PIWAS (above). For
645 spike glycoprotein and nucleoprotein, we averaged PIWAS tiling values for the COVID-19
646 cohort across each proteome. A multiple sequence alignment of all these coronavirus
647 sequences was performed using Clustal Omega⁷². Using this alignment index, we identified
648 regions of divergent and convergent signal across the coronavirus proteomes in the COVID-19
649 population. For regions of interest, we calculated the significance of differences in patient
650 severity using the Wilcoxon rank sum test.

651

652 *GISAID originating laboratories*

653 Proteome sequences of 96,437 SARS-CoV-2 strains were downloaded from the GISAID
654 database. We gratefully acknowledge the authors from the originating laboratories responsible
655 for obtaining these specimens and the submitting laboratories where genetic sequence data
656 were generated and shared via the GISAID initiative^{36,37}. Supplemental Table 3 provides a
657 complete list of these strains, authors, and laboratories used in this manuscript (Supplemental
658 Table 3).

659

660 *SARS-CoV-2 strain analysis*

661 For each of the 96,437 SARS-CoV-2 proteomes, we identified amino acid mutations
662 relative to the original SARS-CoV-2 strain (hCoV-19/Wuhan/WIV04/2019). Incomplete
663 proteomes were not considered. A total of 21,127 unique amino acid mutations were identified
664 across spike glycoprotein, membrane protein, envelope protein, and nucleoprotein. For each
665 mutation, a region of 10 flanking amino acids on either side was considered as the mutated
666 region, for comparison against the same length wild-type region. For every sample, we

667 calculated and compared PIWAS scores for the wild-type and mutant sequences. To assess
668 significance of the observed bias, we generated *in silico* random mutations to these same
669 proteins and performed the same analysis. We compared the actual and random signals using a
670 Kolmogorov-Smirnov test.

671

672 *Data availability statement*

673 Motif enrichment and PIWAS data have been made available at:

674 <https://www.serimmune.com/covidData.zip>

675

676 *Acknowledgements*

677 We would like to thank the entire team at Serimmune who has made this study feasible,
678 including: Jack Coupart, Cameron Gable, Timothy Johnston, Steve Kujawa, Ulysses Leyva,
679 Vikram Mahuvakar, Noah Nasser, Kenyon Plummer, Heidi Smith, Elizabeth Stewart.

680

681 *Author contributions*

682 Conceptualization: WAH, KK, JB, AI, AIK, JCS; Data generation: WAH, KK, JB, EBJ, MC, ACM,
683 CSDC, SFF, LF, JF, GJ, DK, JK, CL, LLL, MCM, LP, JR, RW, EAW, Yale IMPACT Team; Data
684 curation: WAH, KK, JB, EBJ, ACM, LF, DK, JK, CL, LP, AAW; Formal analysis: WAH, KK, JB,
685 AD, MJ, JK, BM, JR, MZ, JCS; Resources: WAH, KK, JB, EBJ, MC, ACM, PSD, CSDC, AD,
686 SFF, LF, JF, MJ, GJ, DK, JK, CL, LLL, BM, MCM, LP, JR, JRS, RW, EAW, MZ, AI, AIK, JCS;
687 Visualization: WAH, KK, JB, MJ, BM, MZ, JCS; Writing- original draft: WAH, KK, JB, MJ, BM,
688 MZ, JCS; Writing- reviewing & editing: WAH, KK, JB, EBJ, MC, ACM, PSD, CSDC, AD, SFF,
689 LF, JF, MJ, GJ, DK, JK, CL, LLL, BM, MCM, LP, JR, JRS, RW, EAW, MZ, AI, AIK, JCS

690

691 *Competing interests*

692 The authors declare the following competing interests: ownership of stocks or shares at
693 Serimmune, paid employment at Serimmune, board membership at Serimmune, and patent
694 applications on behalf of Serimmune.

695

696 **References**

- 697 1. Nishiura, H. *et al.* Estimation of the asymptomatic ratio of novel coronavirus infections
698 (COVID-19). *International Journal of Infectious Diseases* **94**, 154–155 (2020).
- 699 2. Mizumoto, K., Kagaya, K., Zarebski, A. & Chowell, G. Estimating the asymptomatic
700 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond
701 Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* **25**, (2020).
- 702 3. Atyeo, C. *et al.* Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.
703 *Immunity* **53**, 524-532.e4 (2020).
- 704 4. Amrun, S. N. *et al.* Linear B-cell epitopes in the spike and nucleocapsid proteins as
705 markers of SARS-CoV-2 exposure and disease severity. *EBioMedicine* **58**, (2020).
- 706 5. Mathew, D. *et al.* Deep immune profiling of COVID-19 patients reveals distinct
707 immunotypes with therapeutic implications. *Science* **369**, (2020).
- 708 6. Braun, J. *et al.* SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-
709 19. *Nature* (2020). doi:10.1038/s41586-020-2598-9
- 710 7. Mateus, J. *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed
711 humans. *Science* (80-.). eabd3871 (2020). doi:10.1126/science.abd3871
- 712 8. Ehrenfeld, M. *et al.* Covid-19 and autoimmunity. *Autoimmunity Reviews* **19**, (2020).
- 713 9. Gruber, C. *et al.* Mapping Systemic Inflammation and Antibody Responses in Multisystem
714 Inflammatory Syndrome in Children (MIS-C). *Cell* (2020). doi:10.1016/j.cell.2020.09.034

- 715 10. Bastard, P. *et al.* Auto-antibodies against type I IFNs in patients with life-threatening
716 COVID-19. *Science (80-.)*. **370**, (2020).
- 717 11. Kreye, J., Reincke, S. M. & Prüss, H. Do cross-reactive antibodies cause neuropathology
718 in COVID-19? *Nature Reviews Immunology* (2020). doi:10.1038/s41577-020-00458-y
- 719 12. Guilmot, A. *et al.* Immune-mediated neurological syndromes in SARS-CoV-2-infected
720 patients. *J. Neurol.* (2020). doi:10.1007/s00415-020-10108-x
- 721 13. Belongia, E. A. & Osterholm, M. T. COVID-19 and flu, a perfect storm. *Science* (2020).
722 doi:10.1126/science.abd2220
- 723 14. Servick, K. Coronavirus creates a flu season guessing game. *Science* **369**, 890–891
724 (2020).
- 725 15. Marshall, M. The lasting misery of coronavirus long-haulers. *Nature* **585**, (2020).
- 726 16. Nath, A. Long-Haul COVID. *Neurology* **95**, 559–560 (2020).
- 727 17. Perego, E. *et al.* Why the Patient-Made Term ‘Long Covid’ is needed. *Wellcome Open*
728 *Res.* **5**, (2020).
- 729 18. Ibarondo, F. J. *et al.* Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild
730 Covid-19. *N. Engl. J. Med.* (2020). doi:10.1056/nejmc2025179
- 731 19. Edridge, A. W. D. *et al.* Seasonal coronavirus protective immunity is short-lasting. *Nat.*
732 *Med.* (2020). doi:10.1038/s41591-020-1083-1
- 733 20. Shaman, J. & Galanti, M. Will SARS-CoV-2 become endemic? *Science (80-.)*. (2020).
734 doi:10.1126/science.abe5960
- 735 21. Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the
736 transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science (80-.)*.

- 737 **368**, 860–868 (2020).
- 738 22. Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat.*
739 *Med.* (2020). doi:10.1038/s41591-020-0897-1
- 740 23. Wajnberg, A. *et al.* Robust neutralizing antibodies to SARS-CoV-2 infection persist for
741 months. *Science (80-.)*. (2020). doi:10.1126/science.abd7728
- 742 24. Shrock, E. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity and
743 correlates of severity. *Science (80-.)*. (2020). doi:10.1126/science.abd4250
- 744 25. Li, Y. *et al.* Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in
745 COVID-19 patients. *Cellular and Molecular Immunology* **17**, 1095–1097 (2020).
- 746 26. Kamath, K. *et al.* Antibody epitope repertoire analysis enables rapid antigen discovery
747 and multiplex serology. *Sci. Rep.* **10**, 1–9 (2020).
- 748 27. Pantazes, R. J. *et al.* Identification of disease-specific motifs in the antibody specificity
749 repertoire via next-generation sequencing. *Sci. Rep.* **6**, (2016).
- 750 28. Haynes, W. A., Kamath, K., Daugherty, P. S. & Shon, J. C. Protein-based Immunome
751 Wide Association Studies (PIWAS) for the discovery of significant disease-associated
752 antigens. *bioRxiv* 2020.03.18.997759 (2020). doi:10.1101/2020.03.18.997759
- 753 29. Marklund, E. *et al.* Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-
754 19 infection and analysis of IgG non-responders. *PLoS One* **15**, e0241104 (2020).
- 755 30. Hu, W. T. *et al.* Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection,
756 Atlanta, Georgia, USA, 2020. *Emerg. Infect. Dis.* **26**, (2020).
- 757 31. Benton, D. J. *et al.* Receptor binding and priming of the spike protein of SARS-CoV-2 for
758 membrane fusion. *Nature* 1–8 (2020). doi:10.1038/s41586-020-2772-0

- 759 32. Wrobel, A. G. *et al.* SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform
760 on virus evolution and furin-cleavage effects. *Nat. Struct. Mol. Biol.* **27**, 763–767 (2020).
- 761 33. Anand, P., Puranik, A., Aravamudan, M., Venkatakrishnan, A. J. & Soundararajan, V.
762 SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. *Elife* (2020).
763 doi:10.7554/eLife.58603
- 764 34. Hachim, A. *et al.* ORF8 and ORF3b antibodies are accurate serological markers of early
765 and late SARS-CoV-2 infection. *Nat. Immunol.* **21**, (2020).
- 766 35. Young, B. E. *et al.* Effects of a major deletion in the SARS-CoV-2 genome on the severity
767 of infection and the inflammatory response: an observational cohort study. *Lancet* **396**,
768 603–611 (2020).
- 769 36. Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID’s innovative
770 contribution to global health. *Glob. Challenges* **1**, 33–46 (2017).
- 771 37. Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data – from
772 vision to reality. *Eurosurveillance* (2017). doi:10.2807/1560-7917.ES.2017.22.13.30494
- 773 38. Poh, C. M. *et al.* Two linear epitopes on the SARS-CoV-2 spike protein that elicit
774 neutralising antibodies in COVID-19 patients. *Nat. Commun.* (2020). doi:10.1038/s41467-
775 020-16638-2
- 776 39. Wang, X. *et al.* Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome
777 Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. *Clin.*
778 *Infect. Dis.* (2020). doi:10.1093/cid/ciaa721
- 779 40. Zhang, L. *et al.* Antibody responses against SARS coronavirus are correlated with
780 disease outcome of infected individuals. *J. Med. Virol.* **78**, 1–8 (2006).
- 781 41. Schaedel, C. *et al.* Lung symptoms in pseudohypoaldosteronism type 1 are associated

- 782 with deficiency of the α -subunit of the epithelial sodium channel. *J. Pediatr.* **135**, 739–745
783 (1999).
- 784 42. Geller, D. S. *et al.* Autosomal dominant pseudohypoaldosteronism type 1: Mechanisms,
785 evidence for neonatal lethality, and phenotypic expression in adults. *J. Am. Soc. Nephrol.*
786 **17**, 1429–1436 (2006).
- 787 43. Gentzsch, M. & Rossier, B. C. A Pathophysiological Model for COVID-19: Critical
788 Importance of Transepithelial Sodium Transport upon Airway Infection. *Function* **1**,
789 (2020).
- 790 44. Qiao, B. & De La Cruz, M. O. Enhanced binding of SARS-CoV-2 spike protein to receptor
791 by distal polybasic cleavage sites. *ACS Nano* **14**, 10616–10623 (2020).
- 792 45. Zhang, Y. *et al.* Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.
793 *N. Engl. J. Med.* (2020). doi:10.1056/nejmc2007575
- 794 46. Zhang, Y. *et al.* The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through
795 Potently Downregulating MHC-I. *bioRxiv* (2020). doi:10.1101/2020.05.24.111823
- 796 47. Anderson, E. M. *et al.* Seasonal human coronavirus antibodies are boosted upon SARS-
797 CoV-2 infection but not associated with protection. *medRxiv* **7**, 2020.11.06.20227215
798 (2020).
- 799 48. Ng, K. W. *et al.* Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.
800 *Science* (80-.). eabe1107 (2020). doi:10.1126/science.abe1107
- 801 49. Poston, D. *et al.* Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from
802 individuals with recent seasonal coronavirus infection. *medRxiv* (2020).
803 doi:10.1101/2020.10.08.20209650
- 804 50. Wang, L. *et al.* Importance of Neutralizing Monoclonal Antibodies Targeting Multiple

- 805 Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike
806 Glycoprotein To Avoid Neutralization Escape. *J. Virol.* (2018). doi:10.1128/jvi.02002-17
- 807 51. Sui, J. *et al.* Effects of Human Anti-Spike Protein Receptor Binding Domain Antibodies on
808 Severe Acute Respiratory Syndrome Coronavirus Neutralization Escape and Fitness. *J.*
809 *Virology* **88**, 13769–13780 (2014).
- 810 52. Coughlin, M. M. & Prabhakar, B. S. Neutralizing human monoclonal antibodies to severe
811 acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic
812 potential. *Rev. Med. Virol.* **22**, 2–17 (2012).
- 813 53. Hansen, J. *et al.* Studies in humanized mice and convalescent humans yield a SARS-
814 CoV-2 antibody cocktail. *Science (80-.)*. **369**, 1010–1014 (2020).
- 815 54. Baum, A. *et al.* Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational
816 escape seen with individual antibodies. *Science (80-.)*. **369**, 1014–1018 (2020).
- 817 55. Yurkovetskiy, L. *et al.* SARS-CoV-2 Spike protein variant D614G increases infectivity and
818 retains sensitivity to antibodies that target the receptor binding domain. *bioRxiv* (2020).
819 doi:10.1101/2020.07.04.187757
- 820 56. Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
821 Glycoprotein. *Cell* (2020). doi:10.1016/j.cell.2020.02.058
- 822 57. Fernández, A. Structural Impact of Mutation D614G in SARS-CoV-2 Spike Protein:
823 Enhanced Infectivity and Therapeutic Opportunity. *ACS Medicinal Chemistry Letters* **11**,
824 1667–1670 (2020).
- 825 58. Hu, J. *et al.* The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity
826 and decreases neutralization sensitivity to individual convalescent sera. *bioRxiv* (2020).
- 827 59. Zhang, L. *et al.* The D614G mutation in the SARS-CoV-2 spike protein reduces S1

- 828 shedding and increases infectivity. *bioRxiv Prepr. Serv. Biol.* (2020).
829 doi:10.1101/2020.06.12.148726
- 830 60. Chen, J., Wang, R., Wang, M. & Wei, G. W. Mutations Strengthened SARS-CoV-2
831 Infectivity. *J. Mol. Biol.* **432**, 5212–5226 (2020).
- 832 61. UniProt: the universal protein knowledgebase. *Nucleic Acids Res.* **45**, D158–D169
833 (2017).
- 834 62. Sanner, M. F., Olson, A. J. & Spehner, J. C. Reduced surface: An efficient way to
835 compute molecular surfaces. *Biopolymers* **38**, 305–320 (1996).
- 836 63. Huang, J., Gutteridge, A., Honda, W. & Kanehisa, M. MIMOX: A web tool for phage
837 display based epitope mapping. *BMC Bioinformatics* (2006). doi:10.1186/1471-2105-7-
838 451
- 839 64. Mayrose, I. *et al.* Pepitope: Epitope mapping from affinity-selected peptides.
840 *Bioinformatics* (2007). doi:10.1093/bioinformatics/btm493
- 841 65. Berman, H. M. *et al.* The Protein Data Bank. *Nucleic Acids Research* **28**, 235–242
842 (2000).
- 843 66. Burley, S. K. *et al.* RCSB Protein Data Bank: Biological macromolecular structures
844 enabling research and education in fundamental biology, biomedicine, biotechnology and
845 energy. *Nucleic Acids Res.* **47**, D464–D474 (2019).
- 846 67. Hamelryck, T. & Manderick, B. PDB file parser and structure class implemented in
847 Python. *Bioinformatics* (2003). doi:10.1093/bioinformatics/btg299
- 848 68. Cock, P. J. A. *et al.* Biopython: Freely available Python tools for computational molecular
849 biology and bioinformatics. *Bioinformatics* **25**, 1422–1423 (2009).

- 850 69. DeLano, W. L. Pymol: An open-source molecular graphics tool. *CCP4 Newsl. Protein*
851 *Crystallogr.* (2002).
- 852 70. Tibshirani, R. & Hastie, T. Outlier sums for differential gene expression analysis.
853 *Biostatistics* **8**, 2–8 (2007).
- 854 71. Murtagh, F. & Legendre, P. Ward’s Hierarchical Agglomerative Clustering Method: Which
855 Algorithms Implement Ward’s Criterion? *J. Classif.* (2014). doi:10.1007/s00357-014-
856 9161-z
- 857 72. Madeira, F. *et al.* The EMBL-EBI search and sequence analysis tools APIs in 2019.
858 *Nucleic Acids Res.* (2019). doi:10.1093/nar/gkz268
- 859
- 860
- 861
- 862
- 863
- 864
- 865
- 866
- 867
- 868
- 869
- 870
- 871
- 872
- 873
- 874
- 875
- 876
- 877
- 878
- 879
- 880
- 881
- 882
- 883
- 884

885
886
887
888
889
890
891
892

Table 1: SARS-CoV-2 cohorts used for epitope motif discovery

| SARS-CoV-2 Cohorts | | | Training | | Testing | | COVID-19 Test |
|----------------------|---------|--------------------|-------------|--------------|-------------|--------------|------------------------|
| | | | # of Donors | # of Samples | # of Donors | # of Samples | |
| Cohort I | Yale | Inpatient | 91 | 153 | 98 | 177 | NAT and/or serology |
| | | Healthcare Workers | 4 | 4 | 6 | 9 | NAT and/or serology |
| | | Outpatient | 4 | 4 | 5 | 5 | Serology or symptoms |
| Cohort II | LabCorp | Inpatient | | | 188 | 235 | NAT |
| | | Outpatient | | | 10 | 10 | Serology |
| Cohort III | SBCH | In and Outpatient | | | 73 | 82 | NAT, Serology |
| Cohort IV | BioIVT | In and Outpatient | | | 21 | 21 | Serology (20), NAT (1) |
| Cohort V | BCA | Asymptomatic/Mild | | | 79 | 79 | Serology/SERA |
| Total | | | 99 | 161 | 480 | 618 | |
| Prepandemic Controls | | IgG | 497 | 497 | 1500 | 1500 | |
| | | IgM | 430 | 430 | 1498 | 1498 | |

893

894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911

912
913
914
915
916
917

918 **Table 2: SERA SARS-CoV-2 IgG or IgM panel sensitivity as compared with various**
919 **ELISAs in NAT positive subjects**


| Cohort | Serological Test | n | SERA Sensitivity | ELISA Sensitivity |
|---------|---------------------------------|-----|------------------|-------------------|
| | | | (% 95% CI) | (% 95% CI) |
| Yale | Spike S1 IgG and IgM ELISA | 315 | 77 [71.8 - 81.1] | 79 [73.8 - 82.9] |
| LabCorp | Eurolmun S1 ELISA (IgG) | 235 | 82 [76.7 - 86.5] | 75 [69.4 - 80.4] |
| LabCorp | N Antigen ELISA (IgG) | 235 | 82 [76.7 - 86.5] | 86 [80.4 - 89.4] |
| SBCH | Spike S1 IgG and IgM ELISA | 82 | 52 [41.8 - 62.9] | 48 [37.1 - 58.2] |
| SBCH | Nucleoprotein IgG and IgM ELISA | 82 | 52 [41.8 - 62.9] | 50 [39.4 - 60.6] |

920
921
922
923
924
925
926
927
928
929
930
931

932

933

934



935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958


959

960

961

Figure 1: The Serum Epitope Repertoire Analysis (SERA) platform enables high resolution mapping of SARS-CoV-2 antibody repertoires. The SERA assay results in a set of approximately 1 million unique peptides, the “epitope repertoire”, for each individual. Repertoires were deposited in a database and compared with pre-pandemic controls to identify conserved epitopes in SARS-CoV-2 using proteome-dependent and -independent bioinformatic methods. SERA enables analysis of COVID-19 repertoires against any proteome including mutant SARS-CoV-2 strains, human common coronaviruses and the human proteome for discovery of potential autoantigens. The identified epitope signatures can be used to build diagnostic classifiers, to identify correlates of disease severity, and to develop hypotheses based on cases with specific symptoms and/or disease course (neurological, GI, cardio e.g.).

962
963




964

965 **Figure 2: Bioinformatic analysis of SERA antibody repertoires identifies the antigens and**
966 **epitopes involved in the SARS-CoV-2 immune response. (A)** PIWAS statistical ranking
967 of kmer enrichments across the SARS-CoV-2 proteome using the Mann-Whitney false
968 discovery rate (FDR). Multiple antigens in addition to spike and nucleoprotein showed significant
969 enrichment for one or more epitopes. **(B)** PIWAS kmer enrichments from COVID-19 repertoires
970 versus pre-pandemic controls across statistically significant antigens. PIWAS values = number
971 of standard deviations above the mean of 1500 pre-pandemic controls. IMUNE motifs largely
972 mapped to the same epitopes that were identified by PIWAS. Epitopes on spike
973 and nucleoprotein discovered by IMUNE are shown below each antigen (orange bars).
974 **(C)** Longitudinal samples from individual subjects enabled identification of RBD-specific signals
975 that emerged over time but were not conserved across COVID-19 patients.

976
977
978
979
980
981
982


983
984



985

986 **Figure 3: IMUNE-based discovery of IgG and IgM motifs in the SARS-CoV-2 humoral**
 987 **immune response. (A)** Heatmap of IgG and IgM motif log-enrichment values for 579 COVID-19
 988 samples and 1500 pre-pandemic controls. Inset highlights motifs with linear epitope maps to
 989 SARS-CoV-2. **(B)** Sensitivity and specificity of the SARS-CoV-2 IgG/IgM diagnostic classifier
 990 in NAT+ subjects and pre-pandemic controls. Z-scores for each motif were summed to generate
 991 an IgG/IgM composite score. The maximum value for the IgG or IgM for each sample is
 992 shown. Samples above a cutoff of 25 are classified as positive. The sensitivity or specificity of
 993 the SERA panels for all COVID-19 cohorts and controls is shown above each column. **(C)**
 994 Candidate structural mappings for the linear motif LFPQQ and non-mapping motif YWXYFXK
 995 (through its related variant YXXYFXK). Inset highlights the key contact amino acid residues for
 996 the proposed structural localizations of the motifs. (PDB codes: 7A95 and 6ZGG
 997 respectively). **(D)** Neutralization titer vs. log-enrichment for each motif (LFPQQ and YWXYFXK)
 998 shows that samples with the highest enrichment for either motif tend to have higher titer
 999 neutralization activity.


1000
1001
1002
1003
1004
1005
1006
1007



1008

1009 **Figure 4: Significantly different epitope signals are observed in mild, moderate, and**
 1010 **severe cases of COVID-19. (A)** Comparison of SERA total IgG motif panel scores for severe,
 1011 moderate, and mild cases based on motifs used in the diagnostic panel (Figure 3). Colors
 1012 indicate disease severity. **(B)** Severe, moderate, and mild cases of SARS-CoV-2 are clustered
 1013 based on log-enrichment of the top 10 motifs identified by a t-test comparison of severe and
 1014 mild patients. **(C)** Distribution of PIWAS values at SARS-CoV-2 furin cleavage site for severe,
 1015 moderate, and mild cases. **(D)** PIWAS tiling data is shown for the human ENaC- α protein. Insets
 1016 highlight the furin cleavage site with homology to spike (right) and a non-homologous region of
 1017 ENaC- α (left). **(E)** Distribution of PIWAS values for the peak epitope in ORF8 for severe,
 1018 moderate, and mild cases. **(F)** PIWAS tiling of individual samples on the entire ORF8 sequence.
 1019 All p-values were calculated using outlier sum statistical test.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



1020

1021 **Figure 5: Cross-reactivity analysis across coronaviruses reveals shared epitopes and**
 1022 **epitopes specific to SARS-CoV-2.** PIWAS was performed using COVID-19 samples against
 1023 various coronavirus proteomes including SARS-CoV-2, SARS, MERS, and the common hCoV-
 1024 HKU1, OC43, 229E, and NL63. PIWAS tilings for (A) spike and (D) nucleoprotein revealed
 1025 regions of cross-reactivity as well as epitopes only observed against SARS-CoV-2. Clustal
 1026 multiple sequence alignments were performed and visualized below to depict sequence
 1027 similarity and divergence. Distinct epitopes from (B) spike and (E) nucleoprotein showcase
 1028 PIWAS values across the coronaviruses with corresponding clustal alignment sequences below.
 1029 Epitope locations are denoted with asterisks in (A) and (D). Distribution of PIWAS values at
 1030 epitopes from spike (C) and nucleoprotein (F) for severe, moderate, and mild cases, with p-
 1031 values from Wilcoxon-rank sum test.

1032

1033


1034

1035

1036

1037

1038



1039

1040 **Figure 6: Mutations to SARS-CoV-2 are biased towards decreasing immune epitope**
1041 **response.** 21,127 distinct amino acid mutations in spike glycoprotein, nucleoprotein, envelope
1042 protein, and membrane protein in SARS-CoV-2 strains were identified from sequencing data of
1043 96,437 genomes from GISAID. **(A)** For each mutation, the PIWAS value of the wild-type (WT)
1044 sequence was compared to the PIWAS value for the mutated strain (mut). **(B)** Mutations
1045 conferring a significant PIWAS value change ($|PIWAS_{WT} - PIWAS_{mut}| > 3$) for each COVID-19
1046 sample were identified. For each mutation, the number of patients with a significant difference
1047 was counted. **(C)** Exemplary mutations that yielded a decrease in PIWAS values are shown for
1048 membrane protein (top row), nucleoprotein (middle row), and spike (bottom row). **(D)** No
1049 significant immune signal is seen at location 614 of spike, for either the wild-type or the D614G
1050 variant.

1051

1052